RNS Number : 5037L MaxCyte, Inc. 16 May 2022 MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GAITHERSBURG, MD , May 16, 2022 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to
RNS Number : 8601K MaxCyte, Inc. 10 May 2022 MaxCyte Reports First Quarter Financial Results MaxCyte Increases 2022 Core Revenue Growth Guidance to be at least 25% and Reiterates Milestone Revenue Guidance of $4 million GAITHERSBURG, MD , May 10, 2022 - MaxCyte, Inc.
RNS Number : 9104K MaxCyte, Inc. 10 May 2022 MaxCyte announces filing of Form 10-Q for the quarterly period ended March 31, 2022 GAITHERSBURG, MD , May 10, 2022 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell engineering company focused on providing enabling
RNS Number : 1970K MaxCyte, Inc. 04 May 2022 MaxCyte to Participate in Upcoming Investor Conferences GAITHERSBURG, MD , May 4, 2022 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell - engineering company focused on providing enabling platform technologies to advance
RNS Number : 9260J MaxCyte, Inc. 29 April 2022 MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights Gaithersburg, Maryland - 29 April 2022 : MaxCyte (LSE: MXCT), a leading commercial cell - engineering company focused on providing enabling platform technologies to advance
RNS Number : 5031I MaxCyte, Inc. 19 April 2022 MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GAITHERSBURG, MD , April 19, 2022 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform
RNS Number : 1844I MaxCyte, Inc. 13 April 2022 MaxCyte Announces Departure of CFO and Appointment of Ron Holtz as Interim CFO, Announces Preliminary First Quarter 2022 Revenue GAITHERSBURG, MD , April 13, 2022 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering
RNS Number : 8763H MaxCyte, Inc. 11 April 2022 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing
RNS Number : 9191G MaxCyte, Inc. 01 April 2022 MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights Gaithersburg, Maryland - 1 April 2022 : MaxCyte (LSE: MXCT), a leading commercial cell - engineering company focused on providing enabling platform technologies to advance
RNS Number : 2646G MaxCyte, Inc. 28 March 2022 The following amendments have been made to the Grant of Options and PDMR Dealing announcement released on 28 March 2022 at 07:00 under RNS number 1548G. An incorrect Identification Code in section 4.b has been removed.
